Recruiting Schizophrenia Studies in New York
About Schizophrenia Clinical Trials in New York
Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.
There are currently 10 schizophrenia clinical trials recruiting participants in New York, NY. These studies are seeking a combined 2,334 participants. Research is being sponsored by Icahn School of Medicine at Mount Sinai, Newron Pharmaceuticals SPA, Gedeon Richter Plc. and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Schizophrenia Clinical Trials in New York — FAQ
Are there schizophrenia clinical trials in New York?
Yes, there are 10 schizophrenia clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in New York?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.
Are clinical trials in New York free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.
What schizophrenia treatments are being tested?
The 10 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for schizophrenia.
Data updated October 21, 2026 from ClinicalTrials.gov